New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Free cash flow was −$61.7M: capital expenditures were more than operating cash flow. Cash fell by $305.1M. What is a cash flow statement?

Free cash flow
−$61.7M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$305.1M over the period
Where the cash went, in millions of dollars
Operating cash flow−59.9
Capital expenditures−1.8
Free cash flow−61.7
Into investments, net−238.5
Shares issued, net+0.2
Other−5.2
Change in cash−305.1
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow−$52M−$57M−$51M−$60M
Capex−$1.2M−$2.6M−$2.3M−$1.8M
Free cash flow−$53M−$59M−$53M−$62M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+3 more quarters

(56.32) (56.07) (116.24) (58.57)
Depreciation & Amortization
0.81 1.11 1.34 0.59
Non Cash Items (Other)
— 2.79 56.62 (4.81)
Accounts Payable Change
— 0.68 3.10 (2.37)
Change in payables and accrued liability
— (6.00) 6.92 0.94
Change in other assets and liabilities
— 0.72 (2.29) 4.37
Operating Cash Flow
(51.71) (56.78) (50.55) (59.85)
Capital expenditures
(1.15) (2.63) (2.27) (1.82)
Net Aquisitions
0.00 — — —
Short Term Investments Change (Net)
— 21.65 (71.64) (238.48)
Other investing activities
(0.06) — — —
Investing cash flow
(113.52) 19.01 (73.90) (241.87)
Equity Repurchase (Common, Net)
— 0.43 428.61 0.20
Equity Repurchase (Preffered, Net)
— 10.00 0.00 0.00
Other financial activities
— (0.10) (1.69) (3.60)
Financing cash flow
104.71 10.32 426.91 (3.39)
Change in Cash
(60.52) (27.44) 302.46 (305.11)
Beginning Cash
0.00 109.53 0.00 0.00
Ending Cash
(60.52) 82.09 302.46 (305.11)
Stock Based Compensation
— 5.36 11.70 16.98
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(0.63) (4.60) 7.72 2.94
Investments Change (Net)
(112.37) 21.65 (71.64) (238.48)
Issuance/Purchase of Shares
111.08 10.42 428.61 0.20

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026